Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OraGrowtH Phase 3 Trial
NCT06948214Phase 3Recruiting
- Sponsor
- Lumos Pharma, Inc.
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in growth hormone deficiency (GHD) comparing LUM-201 with Placebo (2 arms). Primary endpoint: Annualized Height Velocity at 12 months. Started May 2026; status: recruiting.
02
Drugs
ibutamoren
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT06948214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948214.